Regiane Penaforte Santos
Research Subjects
Regiane Penaforte Santos has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Maria Oliveira Volpe
Faculty of Santa Casa Belo Horizonte, Belo Horizonte, Brazil
3 shared publications - Júlia Vieira Carvalho
Programa de Pós-Graduação Sricto Sensu em Medicina-Biomedicina, Faculdade de Saúde Santa Casa BH, Belo Horizonte 30260-070, Minas Gerais, Brazil
2 shared publications - Paulo Pereira Christo
CIEM MS Research Center, Minas Gerais Medical School, Federal University, Belo Horizonte 30130-090, MG, Brazil
2 shared publications - Pedro Henrique Villar-Delfino
Faculty of Santa Casa Belo Horizonte, Belo Horizonte, Brazil
2 shared publications - Amanda Medeiros Frota Cruz
Programa de Pós-Graduação Sricto Sensu em Medicina-Biomedicina, Faculdade de Saúde Santa Casa BH, Belo Horizonte 30260-070, Minas Gerais, Brazil
1 shared publication - Cláudia Maria Andrade Fernandes Vieira
Ambulatório Obesidade Clínica, Centro de Especialidades Médicas Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte 30150-240, Minas Gerais, Brazil
1 shared publication
Latest Publications
- Open Access
Differential TLR2- and TLR4-Associated Oxidative Responses After Bariatric Surgery: A Cross-Sectional Study in Women
Background/Objectives: Obesity is characterized by chronic low-grade inflammation and oxidative stress, mediated in part by Toll-like receptor (TLR)-associated pathways. Bariatric surgery improves clinical and metabolic parameters, but its effects on TLR-associated reactive oxygen species (ROS) responses in immune cells remain unclear. This study aimed to investigate ROS production following TLR2- and TLR4-associated stimulation in granulocytes from women with obesity before and after bariatric surgery, compared with age-matched non-obese controls. Methods: ROS production was evaluated using a luminol-dependent chemiluminescence assay in granulocytes isolated from women with obesity before (PRE, n = 12) and after (POST, n = 12) bariatric surgery, as well as from age-matched non-obese controls (n = 12). ROS production was assessed under basal conditions and following stimulation with lipopolysaccharide (LPS, a TLR4 agonist) or zymosan (ZY, a TLR2-associated stimulus). Clinical, anthropometric, and biochemical parameters were assessed, and their associations with ROS production were analyzed. Results: Bariatric surgery was associated with significant improvements in clinical and metabolic parameters, although mean BMI in the POST group remained within the obesity range. Granulocytes from the PRE group exhibited increased basal ROS production and enhanced responses following both LPS and ZY stimulation. In the POST group, basal ROS production and the response following ZY stimulation were comparable to those observed in controls, whereas LPS-associated ROS production remained elevated. Correlation analyses showed positive associations between anthropometric and biochemical parameters and ROS production in both PRE and POST groups, with body weight and BMI remaining positively associated with basal and LPS-associated ROS production after surgery. Conclusions: Bariatric surgery was associated with substantial clinical and metabolic improvement but did not completely restore innate immune redox homeostasis. The persistence of TLR4-driven ROS production suggests that some alterations in innate immune redox balance may persist after surgery despite metabolic improvement.
Open AccessDifferential TLR2- and TLR4-Associated Oxidative Responses After Bariatric Surgery: A Cross-Sectional Study in Women
Background/Objectives: Obesity is characterized by chronic low-grade inflammation and oxidative stress, mediated in part by Toll-like receptor (TLR)-associated pathways. Bariatric surgery improves clinical and metabolic parameters, but its effects on TLR-associated reactive oxygen species (ROS) responses in immune cells remain unclear. This study aimed to investigate ROS production following TLR2- and TLR4-associated stimulation in granulocytes from women with obesity before and after bariatric surgery, compared with age-matched non-obese controls. Methods: ROS production was evaluated using a luminol-dependent chemiluminescence assay in granulocytes isolated from women with obesity before (PRE, n = 12) and after (POST, n = 12) bariatric surgery, as well as from age-matched non-obese controls (n = 12). ROS production was assessed under basal conditions and following stimulation with lipopolysaccharide (LPS, a TLR4 agonist) or zymosan (ZY, a TLR2-associated stimulus). Clinical, anthropometric, and biochemical parameters were assessed, and their associations with ROS production were analyzed. Results: Bariatric surgery was associated with significant improvements in clinical and metabolic parameters, although mean BMI in the POST group remained within the obesity range. Granulocytes from the PRE group exhibited increased basal ROS production and enhanced responses following both LPS and ZY stimulation. In the POST group, basal ROS production and the response following ZY stimulation were comparable to those observed in controls, whereas LPS-associated ROS production remained elevated. Correlation analyses showed positive associations between anthropometric and biochemical parameters and ROS production in both PRE and POST groups, with body weight and BMI remaining positively associated with basal and LPS-associated ROS production after surgery. Conclusions: Bariatric surgery was associated with substantial clinical and metabolic improvement but did not completely restore innate immune redox homeostasis. The persistence of TLR4-driven ROS production suggests that some alterations in innate immune redox balance may persist after surgery despite metabolic improvement.
- Open Access
- 21 March 2025
- Published by IMR Press in Journal of Molecular and Clinical Medicine
- Vol. 8 (1)
Edaravone Inhibits Inflammation in Toll-Like Receptor 4-Stimulated PBMNCs from Multiple Sclerosis Patients
Background: Multiple sclerosis (MS) is a neurological disorder that is directly linked to inflammation in the central nervous system (CNS). The activation of toll-like receptors (TLRs) exacerbates neuroinflammation by increasing the production of reactive oxygen species (ROS) and proinflammatory cytokines. Edaravone (EDV) has been proposed as a potential therapy for CNS diseases because of its free radical scavenging and anti-inflammatory properties. This study investigated the effects of EDV on the inflammatory response in TLR4-stimulated peripheral blood mononuclear cells (PBMNCs) from MS patients and a healthy control group. Methods: The impact of EDV on ROS production in lipopolysaccharide (LPS)-stimulated PBMNCs was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) reduction and luminol-dependent chemiluminescence assays. The interleukin (IL)-6 concentration in the PBMNC supernatants was measured using enzyme-linked immunosorbent assay (ELISA). Results: The results showed that ROS production in PBMNCs stimulated using LPS (a TLR4 activator) was significantly inhibited (p < 0.05) by EDV in the MS patients and control group. Additionally, EDV significantly reduced IL-6 secretion in TLR4-stimulated PBMNCs in these groups (p < 0.05). No significant differences were observed between the groups. Conclusion: Our findings suggest that EDV may serve as an adjunctive therapy for MS by reducing ROS and IL-6 production in TLR4-stimulated PBMNCs in MS patients, highlighting its potential in modulating neuroinflammation and oxidative stress.
- 21 March 2025
- Published by IMR Press in Journal of Molecular and Clinical Medicine
- Vol. 8 (1)
Open AccessEdaravone Inhibits Inflammation in Toll-Like Receptor 4-Stimulated PBMNCs from Multiple Sclerosis Patients
Background: Multiple sclerosis (MS) is a neurological disorder that is directly linked to inflammation in the central nervous system (CNS). The activation of toll-like receptors (TLRs) exacerbates neuroinflammation by increasing the production of reactive oxygen species (ROS) and proinflammatory cytokines. Edaravone (EDV) has been proposed as a potential therapy for CNS diseases because of its free radical scavenging and anti-inflammatory properties. This study investigated the effects of EDV on the inflammatory response in TLR4-stimulated peripheral blood mononuclear cells (PBMNCs) from MS patients and a healthy control group. Methods: The impact of EDV on ROS production in lipopolysaccharide (LPS)-stimulated PBMNCs was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) reduction and luminol-dependent chemiluminescence assays. The interleukin (IL)-6 concentration in the PBMNC supernatants was measured using enzyme-linked immunosorbent assay (ELISA). Results: The results showed that ROS production in PBMNCs stimulated using LPS (a TLR4 activator) was significantly inhibited (p < 0.05) by EDV in the MS patients and control group. Additionally, EDV significantly reduced IL-6 secretion in TLR4-stimulated PBMNCs in these groups (p < 0.05). No significant differences were observed between the groups. Conclusion: Our findings suggest that EDV may serve as an adjunctive therapy for MS by reducing ROS and IL-6 production in TLR4-stimulated PBMNCs in MS patients, highlighting its potential in modulating neuroinflammation and oxidative stress.
- Open Access
- 3 September 2024
- Published by Open Exploration Publishing
- Vol. 3 (5) , 362-374
Antioxidant effects of resveratrol in granulocytes from multiple sclerosis patients
Aim: Neuroinflammation is a characteristic of multiple sclerosis (MS). Resveratrol (RSV) has potent antioxidant properties and has emerged as a promising therapeutic agent for various inflammatory diseases. This study investigated the effects of RSV on inflammatory responses via reactive oxygen species (ROS) production and leukocyte cytokine secretion in patients with MS and healthy controls. Methods: The effects of RSV on ROS production in resting and stimulated granulocytes (in the presence of opsonized particles) were assessed using luminol-dependent chemiluminescence. The cytokines interleukin (IL)-10, IL-1β, IL-6, and high mobility group box 1 (HMGB1) in the supernatant of peripheral blood mononuclear cells (PBMNCs) were quantified using enzyme-linked immunosorbent assay (ELISA). Results: RSV significantly downregulated ROS production in resting and stimulated granulocytes in patients with MS and healthy controls. In the control group, RSV reduced IL-6 levels by 49% in the PBMNC supernatant, whereas IL-6 levels remained unchanged in the MS group. Interestingly, higher levels of IL-10 were detected in PBMNC supernatants from patients with MS than in controls. No significant changes were observed in IL-1β and HMGB1 levels in the PBMNC supernatant. Conclusions: Controlling ROS production is a key target for treating inflammatory diseases. Our findings suggest that RSV can effectively modulate ROS production in MS, highlighting its potential as a promising adjunct therapy for controlling oxidative innate immune responses in MS.
- 3 September 2024
- Published by Open Exploration Publishing
- Vol. 3 (5) , 362-374
Open AccessAntioxidant effects of resveratrol in granulocytes from multiple sclerosis patients
Aim: Neuroinflammation is a characteristic of multiple sclerosis (MS). Resveratrol (RSV) has potent antioxidant properties and has emerged as a promising therapeutic agent for various inflammatory diseases. This study investigated the effects of RSV on inflammatory responses via reactive oxygen species (ROS) production and leukocyte cytokine secretion in patients with MS and healthy controls. Methods: The effects of RSV on ROS production in resting and stimulated granulocytes (in the presence of opsonized particles) were assessed using luminol-dependent chemiluminescence. The cytokines interleukin (IL)-10, IL-1β, IL-6, and high mobility group box 1 (HMGB1) in the supernatant of peripheral blood mononuclear cells (PBMNCs) were quantified using enzyme-linked immunosorbent assay (ELISA). Results: RSV significantly downregulated ROS production in resting and stimulated granulocytes in patients with MS and healthy controls. In the control group, RSV reduced IL-6 levels by 49% in the PBMNC supernatant, whereas IL-6 levels remained unchanged in the MS group. Interestingly, higher levels of IL-10 were detected in PBMNC supernatants from patients with MS than in controls. No significant changes were observed in IL-1β and HMGB1 levels in the PBMNC supernatant. Conclusions: Controlling ROS production is a key target for treating inflammatory diseases. Our findings suggest that RSV can effectively modulate ROS production in MS, highlighting its potential as a promising adjunct therapy for controlling oxidative innate immune responses in MS.